SK2502003A3 - Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine - Google Patents
Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine Download PDFInfo
- Publication number
- SK2502003A3 SK2502003A3 SK250-2003A SK2502003A SK2502003A3 SK 2502003 A3 SK2502003 A3 SK 2502003A3 SK 2502003 A SK2502003 A SK 2502003A SK 2502003 A3 SK2502003 A3 SK 2502003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- olanzapine
- methyl
- thieno
- benzodiazepine
- hydrochloride
- Prior art date
Links
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 229960005017 olanzapine Drugs 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 150000004677 hydrates Chemical class 0.000 title abstract description 8
- 238000006243 chemical reaction Methods 0.000 title abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 99
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 32
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 24
- FDWMAKNNNPSUTL-UHFFFAOYSA-N 2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-amine hydrochloride Chemical compound Cl.N1C2=CC=CC=C2N=C(N)C2=C1SC(C)=C2 FDWMAKNNNPSUTL-UHFFFAOYSA-N 0.000 claims description 13
- 150000004683 dihydrates Chemical class 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 10
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 150000004682 monohydrates Chemical class 0.000 claims description 6
- DQHIXWWYDHOZKI-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine hydrate Chemical compound O.CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 DQHIXWWYDHOZKI-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- ZTTWQKYKGNLCCA-UHFFFAOYSA-N 2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-amine Chemical compound N1C2=CC=CC=C2N=C(N)C2=C1SC(C)=C2 ZTTWQKYKGNLCCA-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- RLUJQBLWUQZMDG-UHFFFAOYSA-N toluene;hydrochloride Chemical compound Cl.CC1=CC=CC=C1 RLUJQBLWUQZMDG-UHFFFAOYSA-N 0.000 claims description 2
- YILNLRSTCMXJCX-UHFFFAOYSA-N 2-methyl-10h-thieno[2,3-b][1,5]benzodiazepine;hydrochloride Chemical compound Cl.C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 YILNLRSTCMXJCX-UHFFFAOYSA-N 0.000 claims 3
- QUMRLXXCRQWODL-UHFFFAOYSA-N 1-methylpiperazin-1-ium;chloride Chemical compound [Cl-].C[NH+]1CCNCC1 QUMRLXXCRQWODL-UHFFFAOYSA-N 0.000 claims 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 2
- RCMPJBBSDIVWOQ-UHFFFAOYSA-N 2-methyl-10h-thieno[2,3-b][1,5]benzodiazepine Chemical compound C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 RCMPJBBSDIVWOQ-UHFFFAOYSA-N 0.000 claims 1
- ISPJJFWCADOGLU-UHFFFAOYSA-N methylsulfinylmethane;hydrochloride Chemical compound Cl.CS(C)=O ISPJJFWCADOGLU-UHFFFAOYSA-N 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 238000000113 differential scanning calorimetry Methods 0.000 description 7
- 238000000862 absorption spectrum Methods 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 238000001757 thermogravimetry curve Methods 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- -1 olanzapine hydrates Chemical class 0.000 description 3
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical compound N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BXPGJQXIERWDOS-UHFFFAOYSA-N 2-methyl-3-(4-methylpiperazin-1-yl)-10h-thieno[2,3-b][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C1=C(C)SC2=C1C=NC1=CC=CC=C1N2 BXPGJQXIERWDOS-UHFFFAOYSA-N 0.000 description 1
- FUOBHGGXKJHKDF-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine dihydrate Chemical compound O.O.C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 FUOBHGGXKJHKDF-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN711CH2000 | 2000-08-31 | ||
| IN709CH2000 | 2000-08-31 | ||
| PCT/US2001/007258 WO2002018390A1 (en) | 2000-08-31 | 2001-03-07 | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK2502003A3 true SK2502003A3 (en) | 2004-03-02 |
Family
ID=26324874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK250-2003A SK2502003A3 (en) | 2000-08-31 | 2001-03-07 | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1313742A1 (pt) |
| JP (1) | JP2004507548A (pt) |
| AU (1) | AU2001243475A1 (pt) |
| BR (1) | BR0114031A (pt) |
| CA (1) | CA2420987A1 (pt) |
| CZ (1) | CZ2003566A3 (pt) |
| HU (1) | HUP0300875A3 (pt) |
| IL (1) | IL154688A0 (pt) |
| NO (1) | NO20030926L (pt) |
| RU (1) | RU2003108745A (pt) |
| SK (1) | SK2502003A3 (pt) |
| WO (1) | WO2002018390A1 (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2464306A1 (en) * | 2001-10-29 | 2003-05-08 | Dr. Reddy's Laboratories Ltd. | Olanzapine dihydrate-ii a process for its preparation and use thereof |
| WO2003091260A1 (en) * | 2002-04-23 | 2003-11-06 | Dr. Reddy's Laboratories Limited | Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof |
| WO2003090730A1 (en) * | 2002-04-25 | 2003-11-06 | Generics [Uk] Limited | Novel crystalline forms of celecoxib and other compounds |
| PL196814B1 (pl) * | 2002-05-17 | 2008-02-29 | Inst Farmaceutyczny | Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty |
| ATE500258T1 (de) | 2002-05-31 | 2011-03-15 | Sandoz Ag | Verfahren zur herstellung von olanzapin form i |
| SI21270A (sl) | 2002-07-15 | 2004-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kristalne oblike olanzapina in postopki za njihovo pripravo |
| PL202856B1 (pl) * | 2002-12-20 | 2009-07-31 | Adamed Spo & Lstrok Ka Z Ogran | Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny |
| AU2003300324A1 (en) | 2002-12-24 | 2004-07-22 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms |
| CA2551806A1 (en) | 2003-12-22 | 2005-07-14 | Teva Pharmaceutical Industries, Ltd. | Methods of preparing olanzapine |
| AR047460A1 (es) * | 2004-01-27 | 2006-01-18 | Synthon Bv | Proceso para la fabricacion de acetato de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (acetato de olanzapina) |
| AR047459A1 (es) | 2004-01-27 | 2006-01-18 | Synthon Bv | Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina) |
| US20070072845A1 (en) * | 2004-02-19 | 2007-03-29 | Davuluri Rammohan Rao | Process for the preparation of olanzapine form 1 useful as antipsychotic drug |
| WO2005107375A2 (en) * | 2004-05-06 | 2005-11-17 | Matrix Laboratories Ltd | Process for the preparation of olanzapine form-i |
| ES2289974T1 (es) * | 2004-07-14 | 2008-02-16 | Shasun Chemicals And Drugs Limited | Metodo mejorado para producir la forma i de la olanzapina. |
| EP2264016B1 (en) | 2004-07-14 | 2013-05-01 | Jubilant Organosys Limited | A process for producing pure form form of 2-Methyl-4-(4-Methyl-1-Piperazinyl)-10h-thieno[2,3-B][1,5] benzodiazepine |
| ES2253091B1 (es) | 2004-07-27 | 2007-02-01 | Inke, S.A. | Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo. |
| WO2006025065A1 (en) * | 2004-08-31 | 2006-03-09 | Lee Pharma Private Limited | A process for the preparation of anhydrous olanzopine hydrochloride of form-1 |
| WO2006027800A1 (en) | 2004-09-06 | 2006-03-16 | Shasun Chemicals And Drugs Limited | A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine |
| SI1838716T1 (sl) * | 2005-01-05 | 2011-10-28 | Lilly Co Eli | Olanzapin pamoat dihidrat |
| KR20070113277A (ko) * | 2005-03-21 | 2007-11-28 | 닥터 레디스 레보러터리즈 리미티드 | 올란자핀의 결정 형태 ｉ의 제조방법 |
| HUP0501046A2 (en) * | 2005-11-11 | 2007-08-28 | Egis Gyogyszergyar Nyilvanosan | Process for the preparation of olanzapine |
| US7834176B2 (en) | 2006-01-26 | 2010-11-16 | Sandoz Ag | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E |
| PL381564A1 (pl) | 2007-01-22 | 2008-08-04 | Koźluk Tomasz Nobilus Ent | Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny |
| AU2008249766A1 (en) * | 2007-05-15 | 2008-11-20 | Generics [Uk] Limited | Process for the purification of olanzapine |
| EP2292624A1 (en) | 2009-07-20 | 2011-03-09 | LEK Pharmaceuticals d.d. | Process for the purification of olanzapine |
| CN102093386B (zh) * | 2011-01-05 | 2016-06-01 | 浙江华海药业股份有限公司 | 一种制备奥兰扎平晶型ⅱ的方法 |
| JP6008734B2 (ja) * | 2012-12-20 | 2016-10-19 | 株式会社トクヤマ | オランザピンｉｉ型結晶の製造方法 |
| HUE067028T2 (hu) | 2016-05-31 | 2024-09-28 | Taiho Pharmaceutical Co Ltd | Ribonukleotid reduktáz inhibitor szulfonamid vegyületek vagy sóik rák kezelésére |
| ES2969901T3 (es) | 2017-11-29 | 2024-05-23 | Taiho Pharmaceutical Co Ltd | Cocristal de ácido benzoico y compuesto de sulfonamida para el tratamiento de tumores |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9009229D0 (en) | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
| EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| ZA978515B (en) * | 1996-09-23 | 1999-03-23 | Lilly Co Eli | Intermediates and process for preparing olanzapine |
| JP2001500878A (ja) * | 1996-09-23 | 2001-01-23 | イーライ・リリー・アンド・カンパニー | オランザピン二水和物ｄ |
-
2001
- 2001-03-07 SK SK250-2003A patent/SK2502003A3/sk unknown
- 2001-03-07 HU HU0300875A patent/HUP0300875A3/hu unknown
- 2001-03-07 IL IL15468801A patent/IL154688A0/xx unknown
- 2001-03-07 AU AU2001243475A patent/AU2001243475A1/en not_active Abandoned
- 2001-03-07 CZ CZ2003566A patent/CZ2003566A3/cs unknown
- 2001-03-07 WO PCT/US2001/007258 patent/WO2002018390A1/en not_active Ceased
- 2001-03-07 BR BR0114031-0A patent/BR0114031A/pt not_active IP Right Cessation
- 2001-03-07 EP EP01916449A patent/EP1313742A1/en not_active Withdrawn
- 2001-03-07 CA CA002420987A patent/CA2420987A1/en not_active Abandoned
- 2001-03-07 RU RU2003108745/04A patent/RU2003108745A/ru not_active Application Discontinuation
- 2001-03-07 JP JP2002523905A patent/JP2004507548A/ja active Pending
-
2003
- 2003-02-27 NO NO20030926A patent/NO20030926L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002018390A1 (en) | 2002-03-07 |
| EP1313742A1 (en) | 2003-05-28 |
| BR0114031A (pt) | 2003-09-09 |
| CA2420987A1 (en) | 2002-03-07 |
| NO20030926L (no) | 2003-04-24 |
| NO20030926D0 (no) | 2003-02-27 |
| IL154688A0 (en) | 2003-09-17 |
| RU2003108745A (ru) | 2005-01-10 |
| HUP0300875A2 (hu) | 2003-12-29 |
| HUP0300875A3 (en) | 2005-09-28 |
| CZ2003566A3 (cs) | 2004-01-14 |
| AU2001243475A1 (en) | 2002-03-13 |
| JP2004507548A (ja) | 2004-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK2502003A3 (en) | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | |
| US5591743A (en) | 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives as 5HT1A ligands | |
| DE69530989T2 (de) | Neue pyrimidinderivate und verfahren zu ihrer herstellung | |
| DE69503803T2 (de) | 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament | |
| DK3077375T3 (en) | PROCEDURE FOR LARGE SCALE PREPARATION OF 1 - [(2-BROMPHENYL) SULPHONYL] -5-METHOXY-3 - [(4-METHYL-1-PIPERAZINYL) METHYL] -1H-INDOL-DIMESYLATE-MONOHYDRATE | |
| DE60111752T2 (de) | 7-oxopyridoryrimidine | |
| CZ299248B6 (cs) | Zpusob prípravy olanzapinu a meziprodukty k této príprave | |
| EP4284805A1 (en) | Mk2 inhibitors, the synthesis thereof, and intermediates thereto | |
| WO2002002568A1 (de) | Pyrimidinderivate und ihre verwendung zur prophylaxe and therapie der zerebralen ischämie | |
| MXPA05011103A (es) | Compuestos de quinazolina. | |
| EP1140096A1 (de) | Verwendung von pyrimidinderivaten zur prophylaxe und therapie der zerebralen ischämie | |
| JPH02138266A (ja) | ６‐フェニル‐３‐（ピペラジニルアルキル）‐２，４（１ｈ，３ｈ）‐ピリミジンジオン誘導体 | |
| US7425627B2 (en) | Methods of synthesizing olanzapine | |
| DE2526983A1 (de) | Pyrido/1,2-a/pyrimidinon-derivate und verfahren zu deren herstellung | |
| EA008055B1 (ru) | Кристаллические формы оланзапина и способы их получения | |
| US20040067936A1 (en) | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | |
| JP5315337B2 (ja) | トポテカン塩酸塩の結晶形およびその製造方法 | |
| JP6996032B1 (ja) | ２－ヘテロアリールアミノキナゾリノン誘導体 | |
| US20060183738A1 (en) | Crystalline forms of nevirapine | |
| ZA200301640B (en) | Process for preparation of hydrates of Olanzapine and their conversion into cystalline forms of Olanzapine. | |
| US7714129B2 (en) | Methods of preparing anhydrous aripiprazole form II | |
| MXPA03001827A (es) | Proceso para la preparacion de hidratos de olanzapina y su conversion a formas cristalinas de olanzapina. | |
| CA2496684A1 (en) | Crystalline solid famciclovir forms i, ii, iii and preparation thereof | |
| EP1687300A1 (en) | Process for the preparing ziprasidone monohydrochloride hydrate | |
| CN119775280A (zh) | 一种磷酸芦可替尼中间体及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB9A | Suspension of patent application procedure |